With this approval, Zydus has obtained 415 regulatory clearances and filed 483 Abbreviated New Drug Applications (ANDAs) as ...

Zydus Lifesciences Ltd on Wednesday (March 5) said it has received final approval from the United States Food and Drug ...

Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Ph+, chronic myeloid leukemia ...

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

With annual US sales of $1.81 billion, as per IQVIA MAT data (January 2025), this approval marks a significant milestone for Zydus. The company will manufacture Dasatinib at its Ahmedabad SEZ facility ...

Generic competition for Revlimid, Pomalyst, Sprycel and Abraxane is expected to result in a revenue decline of approximately 18-20% of the Legacy Portfolio. The guidance also reflects an ...